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A portable immunosensor coupled to laser-induced fluorescence (LIF) detection 27
system has been successfully developed. It was applied to the quantitative determination 28
of specific IgG antibodies against H. pylori present in human serum samples. This 29
system is a relevant alternative tool for the diagnostic of peptic ulcer and gastritis 30
diseases produced by H. pylori, which are recognized risk factors for the development 31
of gastric mucosa associated lymphoid tissue lymphoma and gastric adenocarcinoma. 32
More than 50% of the population has been affected by H. pylori, one of the most 33
widespread infections around the world. 34
Our proposed system combines the LIF detection, which offers great sensibility 35
with the specificity of the immunological reactions and the microfluidic technology. 36
The device has a central channel (CC) with packed H. pylori antigen immobilized on 3-37
aminopropyl-modified controlled pore glass (AP-CPG). Antibodies in serum samples 38
reacted immunologically with the immobilized antigen and then, they were determined 39
using alkaline phosphatase (AP) enzyme-labeled second antibodies specific to human 40
IgG. The 4-methylumbelliferyl phosphate (4-MUP), employed as enzymatic substrate, 41
was converted to soluble fluorescent methylumbelliferone by AP, and this fluorescent 42
product was finally quantified by LIF detection system. The calculated detection limits 43
for LIF detection and the ELISA procedure were 0.17 and 2.1 UmL−1, respectively, and 44
the within- and between-assay coefficients of variation were below 5.1%. 45
46
Keywords: Microfluidic system; enzyme immunoassays; LIF detection; Helicobacter 47
pylori; immunosensor; gastric diseases.48
49
1. Introduction50












Helicobacter pylori is a Gram-negative spiral-shaped bacterium which was first 51
described by Warren and Marshall in 1983 [1, 2]. This microorganism, classified as a 52
class I carcinogen by the World Health Organization [3], plays a causative role in the 53
development of gastritis (80–85%), peptic ulcer (10–15%), gastric adenocarcinoma (1–54
2%) and mucosa associated lymphoid tissue (MALT) lymphoma (< 0.01%) [4-7]. More 55
than 50% of the world’s population have H. pylori in their upper gastrointestinal tract, 56
making it the most widespread infection in the world [8].57
According to published articles, the prevalence of this relevant infection has 58
been associated with poor social and economic development [9, 10]; low education 59
level; poor hygiene practices during childhood; absence of sanitary drinking water; 60
absence of a sewage disposal facility during childhood and [11] inadequate food 61
handling [12]. However, is important to take in account that the severity of the gastric 62
damage and the clinical outcome of H. pylori infection is a consequence of a 63
combination of several factors, including host genetic, bacterial virulence, 64
environmental influence and lifestyle. 65
The transmission of H. pylori infection is still poorly understood, but faecal–66
oral, oral–oral and gastro–oral are the most consensual routes of transmission [13, 14].67
H. pylori infection is usually acquired in childhood and it can persist for the lifetime of 68
the host if it is not treated [15].69
The standard recommended treatment for the eradication of this microorganism 70
consist in the combination of a proton pump inhibitor and two antibiotics, 71
clarithromycin with either amoxicillin or metronidazole [16]. For previously described 72
therapy an eradication rate of >90% has been reported [17]. However, the widespread 73
use of antibiotics has generated a relatively high failure rate of about 20-40% of the 74












patients [18, 13] mainly due to antibiotic resistance [19], but also because the bacteria 75
may be present in a protective environment like the stomach mucosal [20].76
Regarding to the diagnosis of H. pylori infection, invasive methods like 77
endoscopy with biopsies for histology, culture, rapid urease test and the noninvasive 78
tests including serological tests and the urea breath test have been reported [21, 22].79
Serological tests are based on the detection of IgG antibodies against H. pylori present 80
inhuman serum samples. This determination proved to be of considerable value in the 81
diagnosis of active H. pylori infection due to the reliable correlation between the 82
presence of this antibodies and gastric mucosal colonization [23, 24]. As mentioned 83
above, one tool for serologic diagnostic of H. pylori infection is the determination of 84
anti-H. pylori IgG antibodies, which is performed using enzyme immunoassay (EIA) in 85
human serum samples to provide an early diagnosis [25].86
Due to the prevalence of the H. pylori infection, the development of a simple, 87
rapid, accurate, and cost-effective diagnostic methods to achieve: ulcer healing, 88
prevention of peptic ulcer recurrence and the reduction of the prevalence of gastric 89
cancer in high-risk populations, becomes important [26].90
The miniaturization of heterogeneous enzyme immunoassays using microfluidic 91
technology [27] as platform represents an interesting alternative tool, due to its 92
advantages, such as high degree of integration, remarkable sensitivity and low regent 93
consumption between them [28].94
With the aim to recognize the antibody/antigen binding event into microfluidic 95
systems, different transduction pathway scan be used, anyway, laser-induced 96
fluorescence (LIF) offers good sensitivity with low detection limits and provides the 97
possibility of make detections in very small sample volumes. In addition, the 98
miniaturization of the excitation source and the detection device has permitted that the 99












whole device can be made easily portable [29]. For these features, LIF detection has 100
become a particularly suitable tool for the detection of several analytes on microfluidic 101
devices in length scales of micrometers or smaller.102
In the presented work, we established a LIF immunosensor incorporated into 103
microfluidic analytical system for a rapid and sensitive quantification of human serum 104
IgG antibodies to H. pylori, based on the use of purified H. pylori antigen that was 105
immobilized on 3-aminopropyl-modified controlled pore glass (AP-CPG). Antibodies in 106
the serum samples were allowed to react immunologically with the antigen, and the 107
bound antibodies were quantified by alkaline phosphatase (AP) enzyme-labeled second 108
antibodies specific to human IgG. 4-methylumbelliferyl phosphate (4-MUP) was 109
converted to soluble fluorescent methylumbelliferone by AP [30, 31] and it was 110
quantified using LIF detection system. The response obtained from the product of 111
enzymatic reaction was proportional to the activity of the enzyme and consequently, to 112
the amount of IgG antibodies to H. pylori antigen in serum.113
114
2. Materials and methods115
2.1. Reagents and solutions116
All reagents used were of analytical reagent grade 3-aminopropyl-modified controlled 117
pore glass (AP-CPG; 1,354 Å mean pore diameter, 19.7 m2g−1 surface area) was 118
purchased from Pure Biotech LLC, Glutaraldehyde (25% aqueous solution) was 119
purchased from Merck,Darmstadt,4-methylumbelliferyl phosphate (4-MUP) and AP 120
enzyme labeled second antibodies specific tohuman-chainwere purchased from Sigma 121
Chemical (St. Louis, MO, USA). The Enzyme Immunoassay for the Quantitative 122
Determination of IgG Class Antibodies to Helicobacter pylori was purchased from 123












EQUIPAR, Diagnostic, (Rome, Italy) and was used in accordance with the 124
manufacturer’s instructions [32]. All buffer solutions were prepared with Milli-Q water. 125
126
2.2. Instrumentation 127
The syringe pumps system (Baby Bee Syringe Pump, Bioanalytical Systems) 128
was used for pumping, sample introduction, and stopping flow.129
All solutions and reagent temperatures were conditioned before the experiment 130
using a Vicking Masson II laboratory water bath (Vicking SRL, Buenos Aires, 131
Argentina).132
Absorbance was detected by Bio-Rad Benchmark microplate reader (Japan) and 133
Beckman DU 520 general UV/VIS spectro photometer.134
The optical system was constructed using the procedure of reference [33] with 135
the following modifications. A 355 nm single-frequency DPSS laser (Cobolt Zouk™, 136
USA) operated at 10 mW served as the fluorescence excitation source. It was focused 137
onto the detection channel at 45° to the surface using a lens with a focal distance of 30 138
cm, as shown in Figure 1a. The relative fluorescence signal of 4-MUP was measured 139
using excitation at 355 nm and emission at 440 nm.140
The paths of the reflected beams were arranged, so that they did not strike the 141
capillary channels elsewhere, in order to avoid photobleaching. The fluorescent 142
radiation was detected with the optical axis of the assembly shown in Figure 1a, 143
perpendicular to the plane of the device. Light was collected with a microscope 144
objective (10: 1, NA 0.30, working distance 6 mm, PZO, Poland) mounted on a 145
microscope body (BIOLAR L, PZO, Poland). A fiber optic collection bundle was 146
mounted in a sealed housing at the exit of the microscope which was connected to 147












QE65000-FL Scientific-grade Spectrometer (Ocean Optics, Inc. USA). The entire 148
assembly was covered with a large box to eliminate the ambient light. 149
All pH measurements were made with an Orion expandable ion analyzer (Orion 150
Research Inc., Cambridge, MA, USA) Model EA 940 equipped with a glass 151
combination electrode (Orion Research Inc.).152
153
2.3. Preparation of the H. pylori antigens154
The antigens were prepared from a sonicated H. pylori culture strain. The H. 155
pylori were grown on blood agar plates at 37°C for3 days and then harvested, washed, 156
and resuspended in 0.01M phosphate-buffered saline (PBS, pH 7.2). This preparation 157
was subjected to sonication. The sonic amplitude level was set at 20%, and the machine 158
was operated using four cycles of 60 s regulated alternatively. The sonicated preparation 159
was centrifuged at 1000×g for 10 min, and the supernatant was stored in the 0.01M PBS 160
(pH 7.2), at −20 ◦C between uses.161
162
2.4. Immobilization of purified antigen of H. pylori on AP-CPG163
To carry out the process of modification, 1 mg of AP-CPG was allowed to react 164
with 1 ml of an aqueous solution of 5% w/w glutaraldehyde in 0.20 M CO3
2-/ HCO3
-165
buffer at pH 10.00 ( for 2 h at room temperature. After three washes with 0.10 M166
phosphate buffer of pH 7.00, 100 μg mL−1 of H. pylori antigen solution was coupled to 167
the residual aldehyde groups overnight at 5°C. The immobilized antigens preparation 168
was finally washed three times with phosphate buffer (pH 7.00) and stored in the same 169
buffer at 5°C. The immobilized H. pylori preparation was perfectly stable for at least 1 170
month.171
172












2.5. Design of microfluidic immunosensor system173
Figure 1b shows a schematic representation of the design of our microfluidic 174
immunosensor which was fabricated using commercially available 3.5 mm thick Poly 175
methyl-methacrylate (PMMA) sheets. PMMA sheets were cut into plates measuring 176
20.0 mm × 50.0 mm (width × length) to form microchip substrates. The microfluidic 177
pattern was designed and then it was sent to the laser scriber for direct machining on 178
PMMA substrate. Once the microfluidic channels were formed, the device was 179
thermally sealing by action of the temperature. The PMMA channel plate and the 180
PMMA cover sheets were sandwiched between two glass plates (of the same 181
dimensions), clamped together using laboratory clamps, and placed in a convection 182
oven for 10 min at 110 °C. The bonded chip was then allowed to cool slowly and the 183
clamps were removed.184
The final device has a CC and accessory channels with diameters of 100 µm. In 185
the CC of the device, H. pylori antigen-AP-CPG was packed and then kept in a fixed 186
previous position of the detection zone because of the CC diameter’s reduction of 100 187
µm to 30 µm, which avoids the loss of this modified support.188
189
2.6. Detection procedure190
The developed method was based on the principle of a heterogeneous non-191
competitive fluorescence immunoassay (Fig. 2). The carrier buffer was 0.01M PBS, pH 192
7.2.The immunological procedure was as follows: unspecific binding was blocked by a 193
5-min treatment at room temperature with 3% skim milk in a 0.01 M phosphate-buffer 194
saline (PBS) pH 7.2 at flow rate of 2.0 μL min−1 and then it was rinsed with 0.01M PBS 195
(pH 7.2) for 5 min at a flow rate of 2.0 μL min−1. After that, serum sample, firstly 196
diluted 100 fold with 0.01 M PBS (pH 7.2), was injected into the PBS carrier stream at 197












flow rate of 2.0 μL min−1 for 5 min. Consequently IgG anti-H. pylori antibodies present 198
in it reacted with H. pylori antigen on the surface of the support (H. pylori antigen-AP-199
CPG). Then the device was washed with 0.01M PBS (pH 7.2) at a flow rate of 2.0 μL 200
min−1for 5 min to remove the exes of sample. Bound antibodies were quantified using 201
alkaline phosphatase enzyme-labeled second antibodies specific to human IgG (dilution 202
of 1/1.000 in 0.01 M PBS, pH 7.2) injected at flow rate of 2.0 μL min−1 for 5 min. Then, 203
the microfluidic system was washed with 0.01 M PBS (pH 7.2) for 4 min.204
The relative fluorescence signal, which corresponded to the IgG specific H. 205
pylori antibodies-alkaline phosphatase enzyme-labeled second antibodies complex was 206
measured ‘in-situ’ in the immune-microfluidic device. 4-MUP fluorescence was 207
measured using excitation at 355 nm and emission at 440 nm. DEA buffer (100 mM 208
diethanolamine, 50 mM KCl, 1 mM MgCl2, pH 9.6) was used to prepare the 4-MUP 209
solution. Finally, 5 µL of substrate solution (2.5mM 4-MUP in DEA buffer, pH 9.6) 210
were injected into the carrier stream at a flow rate of 2 µL min−1, and the enzymatic 211
product was measured by LIF.212
213
3. Results and discussion214
3.1. Immunosensor optimization215
Systematic studies of relevant parameters that affect the performance of 216
immunological reactions were performed.217
218
3.2. Concentration of immobilized H. Pylori antigen219
One of the most important parameter was the antigen concentration employed to 220
the immobilization procedure. The amount of antigen is an important factor, due to it 221
affects the sensitivity of the immunoassay. For this study, the Horseradish peroxidase 222












(HRP) saturation method was used. The optimum value of H. pylori antigen was 100 μg 223
mL-1.224
225
3.3. Flow rate and sample volume226
Other factor studied was the flow rate, which affects the dispersion of the 227
analytes and the yield of the immunological reaction [34]. Pressure-driven flow is one 228
the most widely used mode of fluid delivery for microfluidic immunosensor. In our case 229
the immunoreactants were injected into the microfluidic sensor with a syringe pump 230
system. This parameter was optimized by studying the relative fluorescence obtained for 231
a standard of 100 UR mL−1 at different flow rates between 1-15 μL min−1 (Fig. 3). Flow 232
rates from 1 to 3 μL min−1 had a little effect over signals obtained, when the flow rate 233
exceeded 4 μL min−1, the relative fluorescence was reduced. Then, the flow rate used 234
was 2 μL min−1.235
Another optimized parameter was the sample size, which was analyzed using a 236
standard of 100 UR mL−1, in a range of 1–20 μL. The relative fluorescence increased 237
linearly when the sample size rises from 1 to 10 μL. Insignificant differences were 238
observed when sample size was greater than 10 μL (Fig. 4). Then, a sample size of 10 239
μL was used.240
241
3.4. Optimum pH values242
The influence of pH on the antigen–antibody binding, the immunosensor 243
regeneration and the enzymatic response were carried out varying the pH value of: 244
carrier solution, desorption solution, and substrate solution within a range of 6.5–7.5, 245
2.0–3.0 and 8–10 respectively. The optimum pH range of antigen–antibody binding was 246












7.0–7.4 in PBS solution, the optimum pH value for desorption solution was 2.0 and the 247
rate of enzymatic response showed a maximum value of activity at pH 9.6. 248
249
3.5. Substrate concentration250
An evaluation of the effect of 4-MUP concentration over the enzymatic response 251
was carried out in a range of 0.1–5.0 mM. The optimal 4-MUP concentration found was 252
2.5mM. This concentration was then used.253
254
3.6 Analytical performance255
The proposed method was applied in the quantification of anti-H. pylori IgG 256
antibodies concentration in 22 serum human samples under the conditions described 257
above, and the relative fluorescence response of the enzymatic product is proportional 258
to the concentration of anti-H. pylori specific IgG antibodies in serum samples of 259
infected patients.260
A linear calibration curve to predict the concentration of H. pylori-specific IgG 261
antibodies in serum was produced within the range of 0–100 UmL−1. The linear 262
regression equation was RFU=2.834+5.263*CH. pylori, with the linear regression 263
coefficient r = 0.998. The coefficient of variation (CV) for the determination of 20264
UmL−1H.pylori-specifi  antibody was below 3.2% (six replicates). 265
The ELISA procedure was also carried out following the manufacturer’s 266
protocol [32], absorbance changes were plotted against the corresponding H. pylori-267
specific IgG antibody concentration and a calibration curve was constructed. The linear 268
regression equation was A = 0.137 + 0.029*C H. pylori, with the linear relation 269
coefficient r= 0.995, the CV for the determination of 20 UmL−1H. pylori specific 270
antibodies was 4.7% (six replicates).271












The detection limit (DL) was considered to be the concentration that gives a 272
signal three times the standard deviation (SD) of the blank. For LIF detection and EIA 273
procedure the DLs were 0.17 and 2.1 UmL−1, respectively. This result shows that LIF 274
detection was more sensitive than spectrophotometric method. 275
The precision of the proposed method was carried out with control serum at 20, 276
50 and 100UmL−1H. pylori specific antibody concentrations. The within-assay precision 277
was tested with five measurements in the same run for each serum. These series of 278
analyses were repeated for three consecutive days in order to estimate the between-279
assay precision. The obtained results are shown in Table 2. The H. pylori assay showed 280
good precision; the CV within-assay values were below 3.2% and the between-assay 281
values were below 5%. The accuracy was tested with a dilution test. It was performed 282
with 100 UmL−1H. pylori specific antibodies control sera (Fig. 5). The life-time of the 283
immunosensor was about 30 continuous working days, and it allowed a sample speed 284
about 2 samples h-1. 285
The microfluidic system with LIF detection was compared with a commercial 286
spectrophotometric system for the quantification of H. pylori specific IgG antibody in 287
serum samples. The slopes obtained were reasonably close to 1, indicating high288
correspondence between the two methods (Fig. 6).289
Our group had previously developed bioanalytical sensors for the 290
electrochemical determination of H. pylori specific IgG antibodies in human serum 291
samples [35-38],  in comparison, the new microfluidic device was based on LIF 292
detection system with incorporated optics fibers. Moreover, the achieved DL and the 293
employed sample volume (10 µL) were lower than that obtained by the sensors 294
previously reported [35-38]. In addition, no clean-up of the detection system was 295
needed between analyses in comparison to electrochemical detectors, which make an 296












improvement in time consuming analysis, reproducibility and lifetime of the 297
immunosensor. The advantages above mentioned for our system, combined with its 298
portability and adaptability make our system an attractive and adequate tool to 299
accomplish automated analysis in health references centers.300
301
4. Conclusions302
This article describes the design, development, and application of a microfluidic 303
immunosensor coupled to LIF detection for the quantitative determination of specific 304
IgG antibodies present in serum samples of patients with H. pylori infection.305
Our developed system combines: the high sensitivity of LIF detection and the 306
inherent properties of optical fibers, such as the chemical inertness of the surface, high 307
transmission, flexibility and low cost, with microfluidic technology features as 308
reduction in liquid volumes required for sampling, fluid transfer, and washing of sensor 309
surfaces, which translates into a more rapid manipulations, lower power requirements, 310
and increased portability of the device.311
This biosensor shows major advantages over previously developed bioanalytical 312
sensors for the determination of H. pylori specific IgG antibodies in serum samples, 313
namely better sensitivity provided reaction-detection integration, which is faster, 314
required minimal sample handling and no clean-up of the detection system was required 315
or  needed.316
The obtained results employing our system showed that it has significant 317
potential for performing bioanalytical analysis aimed at the determination of low 318
concentrations of several analytes in relevant fields.319
320
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Figure 1. a) Schematic representation of the optical detection system. DPSS laser light 471
was focused with a lens (1) onto the detection channel (2), which was held in place with 472
a Plexiglas holder (3). Fluorescence emission (4) was collected with a microscope 473
objective (5), focused onto fiber optic collection bundle (6) and then detected with a 474
QE65000-FL Scientific-grade Spectrometer. b) Schematic representation of the 475
microfluidic immunosensor. Central channel. (CC), controlled pore glass (CPG), 476
Detection area (DA). All measurements are given in millimeters.477
478
Figure 2. Schematic representation of the immunological reaction479
480
Figure 3. Effect of flow rate analyzing a 100 U mL-1 H. pylori-specific antibodies 481
standard at different flow rates. 2.5 mM of 4-MUP in DEA buffer pH 9.6 were injected 482
into the carrier stream at different flow rates, and the enzymatic product was measured 483
by LIF using excitation wavelength 355 nm and emission wavelength 440 nm484
485
Figure 4. Effect of sample size for a standard of 100 U mL-1 H.pylori-specific 486
antibodies. 2.5mM of 4-MUP in DEA buffer, pH 9.6 were injected into the carrier 487
stream at a flow rate of 2 µL min−1, and the enzymatic product was measured by LIF 488
using excitation wavelength 355 nm and emission wavelength 440 nm. Each value of 489
current is based on five determinations.490
491
Figure 5. Dilution test results for 100 U mL−1 H. pylori-specific antibodies. 2.5mM of 492
4-MUP in DEA buffer, pH 9.6 were injected into the carrier stream at a flow rate of 2 493












µL min−1, and the enzymatic product was measured by LIF using excitation wavelength 494
355 nm and emission wavelength 440 nm. Each value of current is based on five 495
determinations. Each value of RFU is based on five determinations.496
497
Figure 6. Correlation between proposed method and commercial photometric assays.498
499
500


















Blocking solution 3% skim milk (PBS, pH 7.2) 2.0 µL min−1 5 min
Washing buffer Flow rate: 2.0 µL min-1 (PBS, pH 7.2) 2 min
Serum samples diluted 100-fold 2.0 µL min−1 5 min
Washing buffer Flow rate: 2.0 µL min-1 (PBS, pH 7.2) 4 min
Enzyme conjugated AP-conjugated (dilution of 1/2000) 2.0 µL min-1 5 min
Washing buffer Flow rate: 2.0 µL min-1 (PBS, pH 7.2) 4 min
Sustrate 2.5mM 4-MUP in a DEA buffer, pH 9.6 1 min
LIF detection
Excitation wavelength: 355 nm



























Table 2. Within-assay precision (five measurements in the same run for each control 518
serum) and between-assay precision (five measurements for each control serum, 519
repeated for three consecutive days).520
521
a Control sera Within-assay Between-assay
Mean CV % Mean CV %
20 U mL-1 20.7 3.7 21.0 3.2
50 U mL-1 49.7 1.5 49.5 4.3
100 U mL-1 101.3 2.9 98.8 3.7
a U mL-1 H. pylori specific antibodies522
523
524
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